Vito Quaranta
Overview
Explore the profile of Vito Quaranta including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
114
Citations
4474
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lorenzo G, Jarrett A, Meyer C, DiCarlo J, Virostko J, Quaranta V, et al.
Eng Comput
. 2024 Dec;
40(3):1469-1499.
PMID: 39620056
Supplementary Information: The online version contains supplementary material available at 10.1007/s00366-023-01873-0.
2.
Morris B, Heeke S, Xi Y, Diao L, Wang Q, Rocha P, et al.
bioRxiv
. 2024 Aug;
PMID: 39211077
Introduction: A hallmark of small cell lung cancer (SCLC) is its recalcitrance to therapy. While most SCLCs respond to frontline therapy, resistance inevitably develops. Identifying phenotypes potentiating chemoresistance and immune...
3.
Meyer C, Smith B, Wang J, Teuscher K, Grieb B, Howard G, et al.
Proc Natl Acad Sci U S A
. 2024 Aug;
121(35):e2408889121.
PMID: 39167600
WD40 Repeat Domain 5 (WDR5) is a highly conserved nuclear protein that recruits MYC oncoprotein transcription factors to chromatin to stimulate ribosomal protein gene expression. WDR5 is tethered to chromatin...
4.
Stauffer P, Brinkley J, Jacobson D, Quaranta V, Tyson D
Cancers (Basel)
. 2024 Jul;
16(13).
PMID: 39001489
Drug tolerance is a major cause of relapse after cancer treatment. Despite intensive efforts, its molecular basis remains poorly understood, hampering actionable intervention. We report a previously unrecognized signaling mechanism...
5.
Stauffer P, Brinkley J, Jacobson D, Quaranta V, Tyson D
bioRxiv
. 2023 Nov;
PMID: 37961267
Drug tolerance is a major cause of relapse after cancer treatment. In spite of intensive efforts, its molecular basis remains poorly understood, hampering actionable intervention. We report a previously unrecognized...
6.
Groves S, Quaranta V
Front Netw Physiol
. 2023 Sep;
3:1225736.
PMID: 37731743
Phenotypic plasticity of cancer cells can lead to complex cell state dynamics during tumor progression and acquired resistance. Highly plastic stem-like states may be inherently drug-resistant. Moreover, cell state dynamics...
7.
Beik S, Harris L, Kochen M, Sage J, Quaranta V, Lopez C
PLoS Comput Biol
. 2023 Jul;
19(7):e1011215.
PMID: 37406008
Mechanistic models of biological processes can explain observed phenomena and predict responses to a perturbation. A mathematical model is typically constructed using expert knowledge and informal reasoning to generate a...
8.
Groves S, Panchy N, Tyson D, Harris L, Quaranta V, Hong T
Cancers (Basel)
. 2023 Mar;
15(5).
PMID: 36900269
Small cell lung cancer (SCLC) is an aggressive cancer recalcitrant to treatment, arising predominantly from epithelial pulmonary neuroendocrine (NE) cells. Intratumor heterogeneity plays critical roles in SCLC disease progression, metastasis,...
9.
Nordick B, Chae-Yeon Park M, Quaranta V, Hong T
iScience
. 2022 Oct;
25(10):105224.
PMID: 36248730
Multiple intermediate epithelial-mesenchymal transition (EMT) states reflecting hybrid epithelial and mesenchymal phenotypes were observed in physiological and pathological conditions. Previous theoretical models explaining multiple EMT states rely on regulatory loops...
10.
Taylor D, Meyer C, Graves D, Sen R, Fu J, Tran E, et al.
Front Immunol
. 2022 Sep;
13:936129.
PMID: 36059502
With the clinical approval of T-cell-dependent immune checkpoint inhibitors for many cancers, therapeutic cancer vaccines have re-emerged as a promising immunotherapy. Cancer vaccines require the addition of immunostimulatory adjuvants to...